Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
January 28 2025 - 4:05PM
Business Wire
– Conference Call and Webcast to Follow at 5:00
p.m. ET / 2:00 p.m. PT –
Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth
quarter and full year 2024 financial results will be released on
Tuesday, February 11, 2025 after the markets close. At 5:00 p.m. ET
/ 2:00 p.m. PT, Exelixis management will host a conference call and
webcast to discuss the results and provide a general business
update. Access to the event is available via the Internet from the
company’s website.
To access the conference call, please register using this link.
Upon registration, a dial-in number and unique PIN will be provided
to join the call. To access the live webcast link, log onto
www.exelixis.com and proceed to the Event Calendar page under the
Investors & News heading. A webcast replay of the conference
call will also be archived on www.exelixis.com for one year.
About Exelixis
Exelixis is a globally ambitious oncology company innovating
next-generation medicines and regimens at the forefront of cancer
care. Powered by drug discovery and development excellence, we are
rapidly evolving our product portfolio to target an expanding range
of tumor types and indications with our clinically differentiated
pipeline of small molecules, antibody-drug conjugates and other
biotherapeutics. This comprehensive approach harnesses decades of
robust investment in our science and partnerships to advance our
investigational programs and extend the impact of our flagship
commercial product, CABOMETYX® (cabozantinib). Exelixis is driven
by a bold scientific pursuit to create transformational treatments
that give more patients hope for the future. For information about
the company and its mission to help cancer patients recover
stronger and live longer, visit www.exelixis.com, follow
@ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and
follow Exelixis on LinkedIn.
Exelixis, the Exelixis logo and CABOMETYX are
registered U.S. trademarks.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250128340505/en/
Investors Contact: Varant Shirvanian Director, Investor
Relations Exelixis, Inc. 650-837-7917 vshirvanian@exelixis.com
Media Contact: Hal Mackins For Exelixis, Inc.
415-994-0040 hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Jan 2025 to Feb 2025
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Feb 2024 to Feb 2025
